Connect with us

Hi, what are you looking for?


Goldman Sachs stock price forecast: UBS sees 17% upside

Goldman Sachs Group Inc (NYSE: GS) down nearly 12% versus its year-to-date high is an opportunity for investors to build a position in this quality name, as per a UBS analyst.

Goldman Sachs stock should be worth $385

On Wednesday, Brennan Hawken upgraded the financial services behemoth to “buy” and raised his price target to $385 – about a 17% upside from here.

The analyst is constructive on Goldman Sachs stock because he’s convinced that its trading business could benefit from the recent bank failures.

GS has opportunity to accelerate growth of their asset and wealth management platform and their transactional banking business through attractively priced M&A, especially if stress in banking system presents further inorganic opportunities.

In January, Goldman Sachs said its trading revenue went up 16% (best among peers) in 2022 that helped offset a big hit to its revenue from investment banking.

Why else is he bullish on Goldman Sachs stock?

Earlier this year, Goldman Sachs confirmed that it was shrinking its loss-producing consumer business (read more). That could be a meaningful tailwind for the share price as well, Hawken added.

Other reasons cited for the bullish view on Goldman Sachs stock include the bank’s commitment to expanding its financing business. The analyst said in his research note:

As a [global systemically important bank], the firm is already subject to the highest capital requirements. So, while Basel 4 certainly could increase capital requirements, changes should be less significant than for regional banks.

Goldman Sachs is set to report its Q1 financial results next week. Consensus is for it to earn $8.53 a share this quarter versus $10.76 per share a year ago.

The post Goldman Sachs stock price forecast: UBS sees 17% upside appeared first on Invezz.

Enter Your Information Below To Receive Free Trading Ideas, Latest News And Articles.

    Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

    You May Also Like

    Latest News

    Rep. Jennifer Wexton (D-Va.) announced on Tuesday that she has been diagnosed with Parkinson’s Disease. “If there’s one thing that Democrats and Republicans can...

    Latest News

    After Dianne Feinstein announced she’d contracted the shingles in early March, her staff said she planned to return to the Senate within a matter...


    A U.S. District Court judge has ruled that Elizabeth Holmes, founder and CEO of the disgraced blood-testing company Theranos, cannot remain free on bail...

    Latest News

    SEOUL, South Korea — When a group of American lawmakers arrived in South Korea for meetings with government and military officials, President Yoon Suk-yeol...

    Disclaimer:, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2022 All Rights Reserved.